Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors
作者:Minjin Yoo、Miyoun Yoo、Ji Eun Kim、Heung Kyoung Lee、Chong Ock Lee、Chi Hoon Park、Kwan-Young Jung
DOI:10.1007/s12272-017-0978-y
日期:2018.1
Bromodomain-containing protein 4 (BRD4) is known to regulate the expression of c-Myc to control the proliferation of cancer cells. Therefore, development of small-molecule inhibitors targeting the bromodomain has been widely studied. However, some clinical trials on BRD4 inhibitors have shown its drawbacks such as toxicity including the loss of organ weight. Here, we report the development of the novel and promising scaffold, 1H-indazol-4,7-dione, as a bromodomain inhibitor and synthesized derivatives for the inhibition of binding of bromodomain to acetylated histone peptide. Through this effort, we obtained 6-chloro-5-((2,6-difluorophenyl)amino)-1H-indazole-4,7-dione (5i), which showed a highly potent activity with a half-maximal inhibitory concentration (IC50) of 60 nM. The in vivo xenograft assay confirmed that the 1H-indazol-4,7-dione compound reduced the tumor size significantly. These results show that the 1H-indazol-4,7-dione scaffold is highly potent against bromodomain.
含溴结构域蛋白4(BRD4)被认为调控c-Myc的表达,以控制癌细胞的增殖。因此,针对溴结构域的小分子抑制剂的开发已被广泛研究。然而,一些针对BRD4抑制剂的临床试验显示了其缺点,例如毒性,包括器官重量的丧失。在这里,我们报告了新颖且有前景的骨架1H-吲唑-4,7-二酮作为溴结构域抑制剂的开发,并合成了衍生物以抑制溴结构域与乙酰化组氨酸肽的结合。通过这项工作,我们获得了6-氯-5-((2,6-二氟苯基)氨基)-1H-吲唑-4,7-二酮(5i),该化合物表现出高效的活性,半最大抑制浓度(IC50)为60 nM。在体内异种移植实验中证实,1H-吲唑-4,7-二酮化合物显著降低了肿瘤大小。这些结果表明,1H-吲唑-4,7-二酮骨架对溴结构域具有很高的活性。